All News

The FDA granted fast track designation to irpagratinib for previously treated advanced hepatocellular carcinoma with FGF19 overexpression.

The U.S. FDA granted “study may proceed” clearance for a trial of teverelix in patients with advanced prostate cancer and high cardiovascular risk.

Colleen Mabasa shared her experience navigating CAR-T cell therapy beyond the clinical aspects of treatment.

CURE spoke with breast cancer survivor Mary Royal about her cancer journey in a multipart interview.

Most people think of anniversaries as happy things. But there are other anniversaries that commemorate less pleasant events. Some anniversaries are a mix of pleasant and unpleasant.

In a recent CURE conversation, Charles Walker shared how months of unexplained fatigue and back pain ultimately led to a life-altering diagnosis.

CURE spoke with Dr. Kathie-Ann Joseph about the importance of personalized, multidisciplinary treatments when caring for patients with breast cancer.

A phase 2 trial found oxybutynin safely reduced the frequency and severity of hot flashes in men receiving hormone therapy for prostate cancer.

The U.S. FDA has granted Regenerative Medicine Advanced Therapy designation to KB707 for the treatment of advanced/metastatic non-small cell lung cancer.

Dr. Sue Hwang explains how she went from a care provider who helped others through their cancer journeys to a patient facing a cancer diagnosis of her own.

Drs. Miller, Orringer and Yang explain IDH testing, treatment options, quality of life and caregiver roles for patients with IDH-mutant glioma.

Merkel cell carcinoma is a rare and aggressive form of neuroendocrine skin cancer. While it accounts for a small fraction of all skin cancer cases, its impact is significant.

USC doctors say careful staging and tumor testing help younger patients choose surgery and targeted treatments based on their cancer.

Hodgkin lymphoma is a cancer of the lymphatic system, which includes lymph nodes, the spleen and immune cells that help the body fight infection.

Stage 3 ccRCC is locally advanced but often treatable. Learn how it is diagnosed, treated, and managed to support informed decisions with your care team.

CURE sat down with Dr. Kathie-Ann Joseph to discuss surgical advancements for individuals with breast cancer.

I never thought about mantras until my diagnosis with colon cancer at the age of 34.

Dr. Maral Kibarian Skelsey discussed how advances in genetics and genomics are reshaping the understanding of skin cancer risk and prevention.

Dr. Jesse Miller Lewin sat down with CURE to discuss how advances in systemic and local therapies are reshaping the treatment landscape for skin cancer.

Patients with advanced melanoma experienced high response rates when treated with commercial Amtagvi in a real-world clinical study.

The FDA has granted orphan drug designation to zenocutuzumab-zbco for the treatment of adults with advanced unresectable or metastatic cholangiocarcinoma.

FDA expands access to CAR-T cell therapy for patients with relapsed or refractory PCNSL.

Dr. Elias Obeid says ongoing monitoring after treatment helps detect recurrence early and identify late effects, supporting survivorship for patients.

The U.S. FDA has issued an updated safety communication regarding two commonly used chemotherapy drugs, Xeloda and fluorouracil.

Dr. Suneel Kamath emphasized the growing importance of understanding biomarkers in patients with gastrointestinal cancers.

Relacorilant plus Abraxane showed benefit without biomarker testing, potentially expanding treatment access for patients with platinum-resistant ovarian cancer.

Oral KTX-1001 achieved 40% disease control in phase 1 trials, offering a new targeted therapy for aggressive t(4;14) translocation multiple myeloma.

Relacorilant plus Abraxane improved overall survival by 4.1 months without added toxicity and no biomarker testing in ROSELLA.